Market Trends of Spasticity Treatment Industry
The Cerebral Palsy Segment is Expected to Hold the Major Market Share in the Spasticity Treatment Market
The cerebral palsy (CP) segment is expected to account for the largest of the spasticity drugs market. Factors such as an increase in cerebral palsy cases and a rise in benefits offered by spasticity drugs in treating cerebral palsy are expected to drive the segment growth during the forecast period.
Cerebral palsy is one of the most common childhood disorders witnessed around the globe. An increase in cerebral palsy cases and recurring spasticity is expected to drive the demand for the spasticity treatment market, fueling the segment growth during the forecast period. For instance, as per the January 2024 update by Cerebral Palsy Guidance, around 764,000 people in the United States (including children and adults) have at least one symptom of cerebral palsy. Also, around 10,000 babies are born each year with cerebral palsy. Between 1,200 and 1,500 school-aged children are diagnosed with cerebral palsy each year.
Also, the approval to conduct clinical trials related to CP further facilitates the segment growth during the forecast period. For instance, in January 2024, Neurotech International received approval from the Human Research Ethics Committee (HREC) and clearance from the Therapeutic Goods Administration (TGA) to begin a Phase I/II clinical trial of NTI164 for the treatment of cerebral palsy (CP). The study will investigate the efficacy and safety of NTI164 in pediatric patients with spastic CP, the most prevalent form of CP.
Therefore, owing to the increase in CP cases, growing CP clinical trials, rise in awareness programs, and adoption of spasticity therapies among CP patients, the segment is predicted to grow during the forecast period.
North America is Expected to Dominate the Market During the Forecast Period
North America is expected to dominate the spasticity drugs market owing to the increasing funding for multiple sclerosis (MS) related research coupled with the development of drug delivery solutions in the country. Hence, the following factors and market players’ initiatives to develop drugs to treat spasticity are projected to support the market growth and maintain a similar trend during the forecast period.
The increasing number of people affected by diseases causing spasticity symptoms is likely to drive market growth in the country. According to MS Canada's February 2024 update, Canada has one of the world's highest rates of multiple sclerosis (MS), with around 90,000 Canadians living with the condition. On average, 12 Canadians receive an MS diagnosis every day. Most people are diagnosed with MS between the ages of 20 and 49, and the effects of the disease, which can be unpredictable, persist throughout their lives.
Research on the benefits of drugs in spasticity management is increasing. The research assists in comprehending the advantages of spasticity drugs supported by scientific evidence and enhancing the usage of the drugs. For instance, a study published in March 2023 by the University of Texas Southwestern in the National Library of Medicine concluded that enteral baclofen is a safe and effective medication for treating spasticity in cerebral palsy. This medication is easy to administer and has minimal side effects.
The growing incidence rates of multiple sclerosis and the accessibility of the treatment have supported the country’s growth in the market. Additionally, the increasing availability of cost-effective treatment in the country is anticipated to surge the market growth during the forecast period.
